PDCD1 and Lynch syndrome: A case of a Lynch syndrome patient with mCRC and urothelial cancer was treated sequentially with anti-PD-1 antibody, with atezolizumab (anti-PD-L1), briefly with pembrolizumab, and finally with the combination of ipilimumab (targeting CTLA-4) and nivolumab (targeting PD1).